Compare TBLA & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBLA | TBPH |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | N/A | 2013 |
| Metric | TBLA | TBPH |
|---|---|---|
| Price | $3.15 | $14.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $5.00 | ★ $18.50 |
| AVG Volume (30 Days) | ★ 2.2M | 830.5K |
| Earning Date | 05-06-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | N/A | ★ 2.06 |
| Revenue | N/A | ★ $15,386,000.00 |
| Revenue This Year | $7.63 | $9.51 |
| Revenue Next Year | $5.25 | N/A |
| P/E Ratio | $42.36 | ★ $16.23 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.63 | $7.90 |
| 52 Week High | $4.65 | $21.03 |
| Indicator | TBLA | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 43.45 | 40.20 |
| Support Level | $3.13 | $13.41 |
| Resistance Level | $3.50 | $15.22 |
| Average True Range (ATR) | 0.14 | 0.44 |
| MACD | 0.02 | 0.14 |
| Stochastic Oscillator | 24.42 | 89.80 |
Taboola is a performance-based native advertising network designed to improve click-through rates and increase monetizable events for advertisers while generating yield for publisher websites. Taboola competes with Google, Amazon, and other advertising networks that display stories and products on websites. The company was founded in 2007 in Israel. It acquired Connexity, a retail advertising network, in 2021, and entered a partnership with Yahoo in 2022, in which it acquired exclusive native advertising rights over Yahoo digital properties in exchange for a 25% equity stake in the company.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).